Imaging Somatostatin Receptor Activity in Patients with Active Thyroid Eye Disease Using Tc-99m Depreotide

scientific article published on 01 May 2003

Imaging Somatostatin Receptor Activity in Patients with Active Thyroid Eye Disease Using Tc-99m Depreotide is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/01.RLU.0000063699.88044.D1
P953full work available at URLhttps://journals.lww.com/10.1097/01.RLU.0000063699.88044.D1
P698PubMed publication ID12702954

P2093author name stringNikolaos Pontikides
Themistocles Kaltsas
Gerasimos E. Krassas
Argyrios S. Doumas
P2860cites workImmunosuppressive therapy in patients with thyroid eye disease: an overview of current conceptsQ34199530
Biodistribution on Tc-99m labeled somatostatin receptor-binding peptide (Depreotide, NeoTec) planar and SPECT studies.Q53675683
Somatostatin receptor-binding peptides labeled with technetium-99m: chemistry and initial biological studiesQ71218527
Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye diseaseQ71956083
Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye diseaseQ74484191
P433issue5
P407language of work or nameEnglishQ1860
P921main subjecteye diseaseQ3041498
P304page(s)439-440
P577publication date2003-05-01
P1433published inClinical Nuclear MedicineQ15752866
P1476titleImaging somatostatin receptor activity in patients with active thyroid eye disease using Tc-99m depreotide
Imaging Somatostatin Receptor Activity in Patients with Active Thyroid Eye Disease Using Tc-99m Depreotide
P478volume28

Reverse relations

cites work (P2860)
Q79775301Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial
Q35785161Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy

Search more.